Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities.
It is now well established that any given ligand for a G-protein-couple receptor (GPCR) does not simply possess a single defined efficacy. Rather, a ligand possesses multiple efficacies, depending on the specific down-stream signal transduction pathway analyzed. This diversity may be based on ligand-specific GPCR conformations and is often referred to as "functional selectivity." It has been known for a century that stereoisomers of catecholamines differ in their potency and, in some systems, also in their efficacy. However, the molecular basis for efficacy differences of GPCR ligand stereoisomers has remained poorly defined. In an elegant study published in this issue of Molecular Pharmacology, Woo et al. (p. 158) show that stereoisomers of the beta(2)-adrenoceptor selective agonist fenoterol differentially activates G(s)- and G(i)-proteins in native rat cardiomyocytes. This study is so important because it is the first report to show that even the subtle structural differences within a ligand stereoisomer pair are sufficient to discriminate between GPCR conformations with distinct G-protein coupling properties. The study highlights of how important it is to examine the "more active" (eutomer) and the "less active" (distomer) stereoisomer to understand the mechanisms of action and the cellular effects of GPCR ligands. The study by Woo et al. will ignite a renaissance of the analysis of ligand stereoisomers, using sensitive pharmacological and biophysical assays. The available literature supports the notion that meticulous analysis of ligand stereoisomers is a goldmine for understanding mechanisms of GPCR activation, analysis of signal transduction pathways, development of new therapies for important diseases, and drug safety.
Seifert
Roland
R
Department of Pharmacology, Medical School of Hannover, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. seifert.roland@mh-hannover.de
Dove
Stefan
S
D058666:Adrenergic beta-2 Receptor Agonists; D001665:Binding Sites; D004837:Epinephrine / Q000378:metabolism; D005280:Fenoterol / Q000494:pharmacology; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D008968:Molecular Conformation / Q000187:drug effects*; D009638:Norepinephrine / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011485:Protein Binding; D011487:Protein Conformation; D018343:Receptors, Adrenergic, beta-2 / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000187:drug effects* / Q000378:metabolism*; D012680:Sensitivity and Specificity; D015398:Signal Transduction; D013237:Stereoisomerism
D058666:Adrenergic beta-2 Receptor Agonists; D008024:Ligands; D004364:Pharmaceutical Preparations; D018343:Receptors, Adrenergic, beta-2; D043562:Receptors, G-Protein-Coupled; D005280:Fenoterol; D009638:Norepinephrine; D004837:Epinephrine